By Amanda Lee
Shares of Harbour BioMed soared after the Chinese biopharmaceutical firm announced a collaboration with U.K. pharma giant AstraZeneca, which plans to invest $2.5 billion in China.
The stock rose as much as 28% to 10.00 Hong Kong dollars, equivalent to US$1.29, in early Monday trade in Hong Kong, before paring gains to 7.15%.
AstraZeneca's five-year US$2.5 billion investment, announced on Friday, includes a new research-and-development center in Beijing and a research agreement with Harbour BioMed. The U.K. firm will also acquire 9.15% in newly issued shares of the Hong Kong-listed pharma group.
The collaboration is aimed at discovering and developing next-generation multi-specific antibodies, including for immunology and oncology, Harbour BioMed said separately on Friday.
Under the agreement, Harbour BioMed stands to receive US$175 million in upfront payment, near-term milestone payments and option exercise fees for additional programs. It is also eligible for up to US$4.4 billion in additional development and commercial milestone payments, as well as tiered royalties on future sales.
Harbour BioMed and AstraZeneca may expand their collaboration to additional programs over the next five years, with the option to extend the terms of the agreement for an additional five years, it added.
Harbour BioMed also plans to establish an innovation center in Beijing with AstraZeneca to support the collaboration programs and other joint initiatives.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
March 23, 2025 23:00 ET (03:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。